クリアセル腎臓細胞がん患者の全生存期に対する補助薬療法の影響: 系統的レビューとメタ解析
Dong Lan1, Jianhui Du2, Wenqiang Yuan3
1People's Hospital of Guang'an, Guang'an, China. guangan20160710@163.com.
Urology journal
|September 7, 2025
まとめ
手術後のクリア細胞腎臓がん (ccRCC) の患者では,補助薬療法は生存率を有意に改善しません. このメタアナリシスでは,全生存期,無疾患生存期,または無進行生存期における統計的利益は認められなかった.
科学分野:
- 腫瘍学
- 臨床試験
- バイオ統計学
背景:
- クリアセル腎臓がん (ccRCC) は,最も一般的な腎臓がんサブタイプで,全般的に発生率と死亡率が増加しています.
- 局所的なccRCCでは手術が標準ですが,高リスクの患者では治療結果を改善するために補助療法が検討されています.
- ccRCCの治療戦略を最適化するために,補助薬療法の臨床的有用性を定量化することが重要です.
研究 の 目的:
- ccRCC患者における全生存期 (OS),無疾患生存期 (DFS),無進行生存期 (PFS) に対する補助薬療法の影響を体系的にレビューし,メタ分析する.
- ccRCCの生存エンドポイントの改善における補助薬剤療法の統計的有意性を評価する.
- ccRCC補助治療における臨床的意思決定のための証拠に基づいた洞察を提供すること.
主な方法:
- 2024年10月までの主要なデータベース (Web of Science,Embase,コクラン図書館,PubMed) の包括的な文献検索
- ccRCC患者における補助薬療法を評価するランダム化比較試験 (RCT) を含む.
- OS,DFS,PFSに対する補助療法の効果を統計的に評価するためのメタ分析.
主要な成果:
- 補助薬療法は,対照群と比較して,全生存期 (OS) の統計的に有意な改善を示さなかった.
- 病変の進行のない生存 (PFS) も,補助薬療法の統計的に有意な効果を示さなかった.
- 無病生存期 (DFS) は,補助療法と対照群の間で統計的に有意な違いを示さなかった (P > 0. 05).
結論:
- このメタ解析は,現在の補助薬療法は,CCRCC患者の生存結果を有意に改善しないことを示しています.
- この結果は,CCRCC臨床試験における補助療法戦略とエンドポイントの再評価の必要性を示唆しています.
- 証拠は,情報に基づいた臨床決定とリスクの階層化を支持し,将来のccRCC研究におけるOS主導のエンドポイントの重要性を強調しています.
さらに関連する動画
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
関連する概念動画
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Renal Drug Clearance: Overview
321
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
321
